Therapeutic outcomes of the LHRH antagonists

References

• Srkalovic G, Bokser L, Radulovic S, et al. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Endocrinology. 1990;127(6):3052–3060.
   PubMed Web of Science ®Google Scholar
• Weckermann D, Harzmann R. Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues. Eur Urol. 2004;46:279–284.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA approves drug for patients with advanced prostate cancer [online]. [cited 2009 Jan 5]. Available from: http://www.fda.gov/bbs/topics/NEWS/2008/NEW01935.html
   Google Scholar
• Ferring Pharmaceuticals. European Commission grants Ferring Pharmaceuticals approval of Firmagon (degarelix) for treatment of prostate cancer [online]. cited 2009 Mar 6. Available from: http://www.ferring.com
   Google Scholar
• Astellas Pharma Inc. Gonax (degarelix) for subcutaneous administration: Japanese prescribing information. Tokyo: Astellas Pharma Inc; 2012.
   Google Scholar
• Engel JB, Schally AV. Drug insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007;3:157–167.
   PubMedGoogle Scholar
• Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist. 2000;5:162–168.
   PubMedGoogle Scholar
• Crawford ED, Tombal B, Miller K, et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011;186:889–897.
   PubMed Web of Science ®Google Scholar
• Frampton JE, Lyseng-Williamson KA. Degarelix. Drugs. 2009;69(14):1967–1976.
   PubMed Web of Science ®Google Scholar
• Stangelberger A, Schally AV, Djavan B. New treatment approaches for prostate cancer based on peptide analogues. Eur Urol. 2008;53:890–900.
   PubMed Web of Science ®Google Scholar
• Huirne JAF, Lambalk CB. Gonadotropin-releasing-hormone receptor antagonists. Lancet. 2001;358(9295):1793–1803.
   PubMed Web of Science ®Google Scholar
• Tombal B, Miller K, Boccon-Gibod L, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010;57:836–842.
   PubMed Web of Science ®Google Scholar
• Garnick MB, Gittelman M, Steidle C, et al. Abarelix (PPI-149), a novel and potent GnRH antagonist, induces a rapid and profound prostate gland volume reduction (PGVR) and androgen suppression before brachytherapy (BT) or radiation therapy (XRT). J Urol. 1998;159:220a.
   Web of Science ®Google Scholar
• Broqua P, Riviere PJM, Conn PM, et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharm Exp Ther. 2002;301(1):95–102.
   PubMed Web of Science ®Google Scholar
• Miwa K, Hitaka T, Imada T, et al. Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. J Med Chem. 2011;54(14):4998–5012.
   PubMed Web of Science ®Google Scholar
• Shaw GL, Whitaker H, Corcoran M, et al. The early effects of rapid androgen deprivation on human prostate cancer. Eur Urol. 2016;70(2):214–218.
   PubMed Web of Science ®Google Scholar
• McLeod D, Zinner N, Tomera K, et al. A phase 3, multicenter, open-label, randomized study of Abarelix versus leuprolide acetate in men with prostate cancer. Urology. 2001;58:756–761.
   PubMed Web of Science ®Google Scholar
• Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531–1538.
   PubMed Web of Science ®Google Scholar
• Axcrona K, Aaltomaa S, da Silva CM, et al. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide. BJU Int. 2012;110:1721–1728.
   PubMed Web of Science ®Google Scholar
• Anderson J, Al-Ali G, Wirth M, et al. Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). Urol Int. 2013;90:321–328.
   PubMed Web of Science ®Google Scholar
• Mason M, Maldonado Pijoan X, Steidle C, et al. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide. Clin Oncol. 2013;25:190–196.
   PubMed Web of Science ®Google Scholar
• Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66:1101–1108.
   PubMed Web of Science ®Google Scholar
• Schröder F, Crawford ED, Axcrona K, et al. Androgen deprivation therapy: past, present and future. BJU Int. 2012;109(Suppl 6):1–12.
   PubMed Web of Science ®Google Scholar
• Selvaggi F, Khoe GSS, Van Cangh P, et al. Comparison of abarelix depot (A-D) and goserelin (G) plus bicalutamide (B) in advanced prostate cancer: results of a multicentre, open-label, randomised, phase III study. Eur Urol. 2001;39(Suppl 5):78.
   Google Scholar
• Mongiat-Artus P, Teillac P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin Pharmacother. 2004;5:2171–2179.
   PubMed Web of Science ®Google Scholar
• Debruyne F, Bhat G, Garnick MB. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. Future Oncol. 2006;2:677–696.
   PubMedGoogle Scholar
• Soul JW. Utility of LHRH antagonists for advanced prostate cancer. Can J Urol. 2014;21(Suppl 1):22–27.
   PubMed Web of Science ®Google Scholar
• Kimura T, Sasaki H, Akazawa K, et al. Gonadotropin-releasing hormone antagonist: a real advantage? Urol Oncol. 2015;33(7):322–328.
   PubMed Web of Science ®Google Scholar
• Mason M, Richaud P, Bosnyak Z, et al. Degarelix versus goserelin plus bicalutamide in the short-term relief of lower urinary tract symptoms in prostate cancer patients: results of a pooled analysis. Low Urin Tract Symptoms. 2017;9(2):82–88.
   PubMed Web of Science ®Google Scholar
• Abbate A, Bussani R, Liuzzo G, et al. Sudden coronary death, fatal acute myocardial infarction and widespread coronary and myocardial inflammation. Heart. 2008;94:737–742.
   PubMed Web of Science ®Google Scholar
• Smith MR, Klotz L, van der Meulen E, et al. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol. 2011;186:1835–1842.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Jun 17. Identifier NCT02663908, A Trial Comparing Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Advanced Prostate Cancer and Cardiovascular Disease (PRONOUNCE); 2016 Jan 22 [cited 2017 Sep 5]; Available from: https://clinicaltrials.gov/ct2/show/NCT02663908.
   Google Scholar
• Mottet N, Bellmunt J, Briers E, et al. EAU–ESTRO–ESUR–SIOG guidelines on prostate cancer. Eur Assoc Urol. 2017. Available from: http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_2017_web.pdf
   Web of Science ®Google Scholar
• Shore ND. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2013;5(1):11–24.
   PubMedGoogle Scholar
• Shore ND, Abrahamsson PA, Andersone J, et al. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013;16:7–15.
   PubMed Web of Science ®Google Scholar
• Clinton TN, Woldu SL, Raj GV. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer. Expert Opin Pharmacother. 2017;18(8):825–832.
   PubMed Web of Science ®Google Scholar
• Carter NJ, Keam SJ. Degarelix: a review of its use in patients with prostate cancer. Drugs. 2014;74:699–712.
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, van der Meulen E, Persson B-E. An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer. Ther Adv Urol. 2011;3(3):127–140.
   PubMedGoogle Scholar
• Secin FP. Questionable oncologic benefits of degarelix. Urol Oncol. 2016;34(10):423–426.
   PubMed Web of Science ®Google Scholar
• Sayyid RK, Evans A, Hersey K, et al. A phase II, randomized, open-label study of neoadjuvant degarelix versus LHRH agonist in prostate cancer patients prior to radical prostatectomy. Clin Cancer Res. 2017;23(8):1974–1980.
   PubMed Web of Science ®Google Scholar
• Tornoe CW, Agerso H, Nielsen HA, et al. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist Degarelix. Pharm Res. 2004;21(4):574–584.
   PubMed Web of Science ®Google Scholar
• Lu L, Peters J, Roome C, et al. Cost–effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer. BJU Int. 2012;109(8):1183–1192.
   PubMed Web of Science ®Google Scholar
• Hatoum HT, Crawford ED, Nielsen SK, et al. Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. Expert Rev Pharmacoeconomics Outcomes Res. 2013;13:261–270.
   PubMed Web of Science ®Google Scholar
• Mourmouris P, Efstathiou E, Papatsoris A. Androgen deprivation therapy and cardiovascular risk. Nephrourol Mon. 2013 Winter;5(1):653–654.
   PubMedGoogle Scholar
• Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013;368:1314–1325.
   PubMed Web of Science ®Google Scholar
• Ozono S, Tsukamoto T, Naito S, et al. Efficacy and safety of a 3-month dosing regimen of degarelix in Japanese patients with prostate cancer: a phase II maintenance-dose-finding study. Jpn J Clin Oncol. 2017;47(5):438–446.
   PubMed Web of Science ®Google Scholar
• MacLean DB, Shi H, Faessel HM, et al. Medical castration using the investigational oral GnRH antagonist TAK-385 (Relugolix): phase 1 study in healthy males. J Clin Endocrinol Metab. 2015;100:4579–4587.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Jun 17. Identifier NCT02141659, This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer; 2014 May 15 [cited 2017 Sep 5]; Available from: https://www.clinicaltrials.gov/ct2/show/NCT02141659.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Jun 17. Identifier NCT02135445, Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer; 2014 May 8 [cited 2017 Sep 5]; Available from: https://www.clinicaltrials.gov/ct2/show/NCT02135445.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Jun 17. Identifier NCT03085095, A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer (HERO); 2017 Mar 9 [cited 2017 Sep 5]; Available from: https://www.clinicaltrials.gov/ct2/show/NCT03085095.
   Google Scholar
• ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2017 Jun 17. Identifier NCT02083185, A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Patients With Prostate Cancer; 2014 Mar 6 [cited 2017 Sep 5]; Available from: https://www.clinicaltrials.gov/ct2/show/NCT02083185.
   Google Scholar
• Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367:895–903.
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, Albers P, Morote J, et al. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. Eur Urol. 2014;66:655–663.
   PubMed Web of Science ®Google Scholar